



Final Appraisal Recommendation

Advice No: 1516 – June 2016

Olanzapine (ZypAdhera®) 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection

Submission by Eli Lilly & Co Ltd

Recommendation of AWMSG

Olanzapine (ZypAdhera®) is recommended as an option for restricted use within NHS Wales.

Olanzapine (ZypAdhera®) is licensed for the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.

Olanzapine (ZypAdhera®) is restricted for use in a subpopulation of patients more appropriately managed with a long acting injection formulation because of difficulties adhering to an oral olanzapine regimen, indicated by recurrent relapse or exacerbation of symptoms.

Olanzapine (ZypAdhera®) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2991), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Eli Lilly & Co Ltd
Date of first issue	June 2016
Last reviewed	July 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1516:
Olanzapine (ZypAdhera®) 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release
suspension for injection. June 2016.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>